



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

April 2021





© 2021 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

April 2021

N = 7436



Health Authority	Male	Female	All
FRASER	1460	447	1907
INTERIOR	431	100	531
NORTHERN	137	84	221
VANCOUVER COASTAL	3352	443	3795
VANCOUVER ISLAND	794	160	954
	6174	1234	7408
		Unknown/not stated:	28
		Total:	7436

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (April 2016 - April 2021)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (April 2016 - April 2021)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (April 2016 - April 2021)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (April 2016 - April 2021)






1.6 Percent Distribution of Active Participants by CD4 Count
(April 2016 - April 2021)






1.7 Percent Distribution of Inactive Participants by CD4 Count (April 2016 - April 2021)






1.8 Active and Inactive Participants (April 2016 - April 2021)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (April 2016 - April 2021)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT
(April 2016 - April 2021)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(April 2016 - April 2021)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT
(April 2016 - April 2021)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(April 2016 - April 2021)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (April 2016 - April 2021)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(April 2016 - April 2021)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (April 2016 - April 2021)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(April 2016 - April 2021)






1.18 Baseline CD4 for Antiretroviral First Starts
(April 2016 - April 2021)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (April 2016 - April 2021)






1.20 Cumulative Resistance Testing Results by Resistance Category (April 2016 - April 2021)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (April 2016 - April 2021)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	29	5	0	5	2	615	5	<40	4
1988	30	5	0	5	3	650	5	<40	3
1989	28	53	1	54	26	520	48	<40	3
1990	27	53	1	54	31	540	51	<40	3
1991	27	37	3	40	21	560	37	<40	3
1992	27	60	5	65	33	530	61	<40	3
1993	26	123	14	137	90	520	130	<40	3
1994	24	77	12	89	58	600	81	<40	3
1995	24	128	19	147	101	530	143	<40	3
1996	22	316	45	361	230	590	342	<40	3
1997	20	275	33	308	207	590	282	<40	3
1998	20	195	43	238	161	560	212	<40	3
1999	19	155	39	194	128	575	172	<40	3
2000	20	120	32	152	105	640	139	<40	3
2001	19	118	27	145	95	630	131	<40	3
2002	18	124	24	148	96	595	134	<40	3
2003	18	140	26	166	109	610	152	<40	3
2004	16	149	37	186	118	590	165	<40	3
2005	16	183	41	224	152	645	199	<40	3
2006	15	172	41	213	146	610	195	<40	3
2007	14	236	49	285	189	610	253	<40	3
2008	13	279	67	346	246	660	313	<40	3
2009	12	302	64	366	240	625	324	<40	3
2010	11	261	67	328	228	650	289	<40	3
2011	10	328	70	398	256	700	344	<40	3
2012	9	270	62	332	212	705	291	<40	3
2013	8	260	63	323	216	705	282	<40	3
2014	7	277	50	327	194	692	286	<40	3
2015	6	276	45	321	223	730	294	<40	3
2016	5	262	55	317	203	680	272	<40	3
2017	4	218	32	250	176	670	229	<40	3
2018	3	195	56	251	168	700	229	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	2	232	42	274	196	620	244	<40	3
2020	1	195	56	251	189	660	234	<40	3
2021	0	88	16	104	95	500	98	<40	3
Total:		6167	1237	7404					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	7358	774	2227	<40	1727	610
FEB-2020	7330	776	1882	<40	1417	620
MAR-2020	7387	768	1628	<40	1207	620
APR-2020	7408	770	767	<40	577	600
MAY-2020	7398	776	1186	<40	892	600
JUN-2020	7374	783	1558	<40	1147	620
JUL-2020	7344	794	1917	<40	1436	610
AUG-2020	7268	791	1847	<40	1330	630
SEP-2020	7248	784	1735	<40	1239	620
OCT-2020	7279	776	1782	<40	1305	630
NOV-2020	7361	764	1858	<40	1278	610
DEC-2020	7365	752	1542	<40	1082	630
JAN-2021	7398	741	1941	<40	1366	630
FEB-2021	7386	748	1786	<40	1233	630
MAR-2021	7448	743	2017	<40	1366	630
APR-2021	7436	746	1828	<40	1230	640

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	635	185	70	354	46	435
FEB-2020	675	173	71	<40	58	480
MAR-2020	632	188	50	<40	32	415
APR-2020	611	204	28	116	22	555
MAY-2020	630	187	42	<50	30	490
JUN-2020	662	181	56	<40	46	480
JUL-2020	729	161	72	<40	56	625
AUG-2020	820	142	75	<40	65	470
SEP-2020	872	137	93	<40	71	610
OCT-2020	866	178	87	<40	75	570
NOV-2020	794	192	78	<40	62	510
DEC-2020	797	187	65	<40	54	430
JAN-2021	781	204	73	<40	55	510
FEB-2021	797	199	70	<40	56	510
MAR-2021	779	252	88	<40	70	630
APR-2021	809	262	73	<40	57	610

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2020	7328	635	10	12	183	155	18	13903
FEB-2020	7295	675	12	19	141	172	-33	13939
MAR-2020	7358	632	14	23	210	152	63	13975
APR-2020	7382	611	12	8	158	127	24	14000
MAY-2020	7375	630	10	15	130	135	-7	14025
JUN-2020	7346	662	8	9	125	149	-29	14042
JUL-2020	7309	729	15	12	160	189	-37	14074
AUG-2020	7222	820	18	11	168	241	-87	14094
SEP-2020	7193	872	19	9	228	241	-29	14115
OCT-2020	7227	866	20	13	223	175	34	14136
NOV-2020	7311	794	12	12	244	155	84	14162
DEC-2020	7327	797	10	13	205	189	16	14191
JAN-2021	7365	781	14	10	203	159	38	14211
FEB-2021	7355	797	15	14	184	192	-10	14235
MAR-2021	7414	779	14	24	203	153	59	14272
APR-2021	7404	809	13	9	166	170	-10	14297

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2020	60	6758	484	56	7358	0.82%	91.85%	6.58%	0.76%	100.00%
FEB-2020	59	6736	477	58	7330	0.80%	91.90%	6.51%	0.79%	100.00%
MAR-2020	60	6790	487	50	7387	0.81%	91.92%	6.59%	0.68%	100.00%
APR-2020	61	6814	483	50	7408	0.82%	91.98%	6.52%	0.67%	100.00%
MAY-2020	60	6807	481	50	7398	0.81%	92.01%	6.50%	0.68%	100.00%
JUN-2020	59	6779	485	51	7374	0.80%	91.93%	6.58%	0.69%	100.00%
JUL-2020	62	6762	472	48	7344	0.84%	92.08%	6.43%	0.65%	100.00%
AUG-2020	71	6688	458	51	7268	0.98%	92.02%	6.30%	0.70%	100.00%
SEP-2020	86	6653	457	52	7248	1.19%	91.79%	6.31%	0.72%	100.00%
OCT-2020	107	6659	462	51	7279	1.47%	91.48%	6.35%	0.70%	100.00%
NOV-2020	162	6693	457	49	7361	2.20%	90.93%	6.21%	0.67%	100.00%
DEC-2020	180	6675	461	49	7365	2.44%	90.63%	6.26%	0.67%	100.00%
JAN-2021	205	6695	452	46	7398	2.77%	90.50%	6.11%	0.62%	100.00%
FEB-2021	226	6661	448	51	7386	3.06%	90.18%	6.07%	0.69%	100.00%
MAR-2021	250	6683	464	51	7448	3.36%	89.73%	6.23%	0.68%	100.00%
APR-2021	275	6661	456	44	7436	3.70%	89.58%	6.13%	0.59%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	2 8%	3402 47%	2 8%	3226 45%	0 0%	34 0%	0 0%	1 0%	9 38%	1024 14%	13 54%	2963 41%	22 92%	3763 52%
FEB-2020	3 8%	3352 47%	3 8%	3180 45%	0 0%	33 0%	0 0%	1 0%	16 44%	1169 16%	17 47%	2825 40%	33 92%	3781 53%
MAR-2020	5 14%	3325 46%	5 14%	3160 44%	1 3%	34 0%	0 0%	1 0%	20 56%	1326 18%	11 31%	2719 38%	30 83%	3855 54%
APR-2020	6 24%	3298 46%	5 20%	3137 43%	1 4%	35 0%	0 0%	0 0%	8 32%	1402 19%	11 44%	2637 37%	19 76%	3888 54%
MAY-2020	1 4%	3273 45%	0 0%	3112 43%	0 0%	36 0%	0 0%	0 0%	13 54%	1481 21%	11 46%	2595 36%	23 96%	3914 54%
JUN-2020	5 29%	3244 45%	5 29%	3082 43%	0 0%	33 0%	0 0%	0 0%	4 24%	1587 22%	8 47%	2519 35%	12 71%	3925 55%
JUL-2020	6 19%	3205 45%	4 13%	3045 43%	2 6%	32 0%	0 0%	0 0%	14 44%	1697 24%	12 38%	2422 34%	26 81%	3946 55%
AUG-2020	3 15%	3154 45%	2 10%	2995 42%	0 0%	31 0%	0 0%	0 0%	11 55%	1763 25%	6 30%	2317 33%	17 85%	3921 55%
SEP-2020	3 14%	3127 44%	2 10%	2966 42%	0 0%	31 0%	0 0%	0 0%	13 62%	1873 26%	5 24%	2227 32%	18 86%	3935 56%
OCT-2020	2 10%	3127 44%	2 10%	2950 42%	0 0%	29 0%	0 0%	0 0%	12 57%	1975 28%	7 33%	2137 30%	19 90%	3967 56%
NOV-2020	7 27%	3170 44%	3 12%	2940 41%	1 4%	30 0%	0 0%	0 0%	11 42%	2073 29%	8 31%	2081 29%	19 73%	4004 56%
DEC-2020	3 10%	3158 44%	3 10%	2902 40%	0 0%	29 0%	0 0%	0 0%	14 48%	2151 30%	12 41%	2023 28%	26 90%	4021 56%
JAN-2021	2 10%	3159 44%	1 5%	2886 40%	0 0%	28 0%	0 0%	0 0%	12 60%	2225 31%	6 30%	1965 27%	18 90%	4053 56%
FEB-2021	2 8%	3141 44%	2 8%	2848 39%	0 0%	27 0%	0 0%	0 0%	16 67%	2300 32%	6 25%	1900 26%	22 92%	4064 56%
MAR-2021	8 22%	3146 43%	7 19%	2837 39%	0 0%	25 0%	0 0%	0 0%	23 62%	2374 33%	6 16%	1861 26%	29 78%	4120 57%
APR-2021	2 8%	3147 43%	2 8%	2811 39%	0 0%	26 0%	0 0%	0 0%	17 68%	2428 33%	6 24%	1794 25%	23 92%	4113 57%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		saquinavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	2 0%	0 0%	910 37%	6 86%	1466 59%	1 14%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2020	0 0%	2 0%	1 11%	873 36%	8 89%	1454 60%	0 0%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAR-2020	0 0%	2 0%	1 10%	860 36%	9 90%	1434 60%	0 0%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
APR-2020	0 0%	2 0%	0 0%	838 36%	4 80%	1412 60%	1 20%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAY-2020	0 0%	2 0%	1 10%	834 36%	9 90%	1411 60%	0 0%	89 4%	0 0%	0 0%	0 0%	6 0%	0 0%	0 0%
JUN-2020	0 0%	2 0%	2 33%	813 35%	4 67%	1388 61%	0 0%	86 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JUL-2020	0 0%	1 0%	0 0%	782 35%	8 100%	1362 61%	0 0%	81 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
AUG-2020	0 0%	1 0%	1 20%	752 35%	4 80%	1331 62%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
SEP-2020	0 0%	0 0%	1 33%	737 35%	2 67%	1303 61%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
OCT-2020	0 0%	0 0%	0 0%	711 34%	6 100%	1285 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
NOV-2020	0 0%	1 0%	0 0%	696 34%	3 100%	1273 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
DEC-2020	0 0%	1 0%	1 8%	680 33%	11 92%	1288 63%	0 0%	76 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JAN-2021	0 0%	1 0%	0 0%	657 32%	5 100%	1298 64%	0 0%	71 3%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2021	0 0%	1 0%	0 0%	643 33%	5 100%	1263 64%	0 0%	71 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
MAR-2021	0 0%	1 0%	1 25%	621 32%	3 75%	1265 65%	0 0%	73 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
APR-2021	0 0%	1 0%	0 0%	597 31%	4 100%	1234 65%	0 0%	71 4%	0 0%	1 0%	0 0%	2 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	1 0%	3 100%	590 36%	0 0%	202 12%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0 0%	1 0%	1 50%	536 36%	0 0%	193 13%	0 0%	452 30%	1 50%	305 21%
JUN-2020	0 0%	1 0%	2 100%	524 36%	0 0%	189 13%	0 0%	448 30%	0 0%	307 21%
JUL-2020	0 0%	3 0%	2 50%	507 35%	0 0%	184 13%	2 50%	439 31%	0 0%	305 21%
AUG-2020	1 100%	4 0%	0 0%	501 36%	0 0%	179 13%	0 0%	423 30%	0 0%	294 21%
SEP-2020	0 0%	5 0%	1 33%	476 35%	0 0%	174 13%	0 0%	410 30%	2 67%	294 22%
OCT-2020	0 0%	9 1%	1 100%	462 35%	0 0%	173 13%	0 0%	402 30%	0 0%	279 21%
NOV-2020	0 0%	10 1%	2 67%	452 35%	0 0%	172 13%	1 33%	393 30%	0 0%	279 21%
DEC-2020	0 0%	11 1%	2 67%	439 35%	0 0%	164 13%	0 0%	383 30%	1 33%	276 22%
JAN-2021	0 0%	11 1%	1 100%	427 34%	0 0%	164 13%	0 0%	379 30%	0 0%	272 22%
FEB-2021	0 0%	15 1%	0 0%	418 34%	0 0%	162 13%	0 0%	365 30%	0 0%	267 22%
MAR-2021	0 0%	21 2%	2 100%	419 34%	0 0%	162 13%	0 0%	366 30%	0 0%	267 22%
APR-2021	0 0%	20 2%	1 50%	409 34%	0 0%	155 13%	1 50%	360 30%	0 0%	261 22%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	9 50%	421 10%	7 39%	2687 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2643 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2623 58%	1 4%	623 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	827 18%	6 43%	2589 57%	1 7%	607 13%	0 0%	29 1%	0 0%	544 12%
MAY-2020	10 56%	911 20%	6 33%	2555 56%	2 11%	597 13%	0 0%	27 1%	0 0%	541 12%
JUN-2020	4 31%	1024 22%	9 69%	2538 55%	0 0%	582 13%	1 8%	28 1%	0 0%	538 12%
JUL-2020	9 38%	1142 24%	10 42%	2512 54%	5 21%	549 12%	0 0%	29 1%	0 0%	527 11%
AUG-2020	10 59%	1221 26%	6 35%	2462 52%	1 6%	517 11%	0 0%	29 1%	0 0%	521 11%
SEP-2020	13 87%	1340 28%	2 13%	2442 51%	0 0%	498 10%	0 0%	29 1%	0 0%	504 11%
OCT-2020	10 59%	1447 30%	5 29%	2430 50%	0 0%	493 10%	0 0%	30 1%	2 12%	495 10%
NOV-2020	8 36%	1548 31%	9 41%	2481 50%	2 9%	482 10%	0 0%	27 1%	3 14%	490 10%
DEC-2020	10 53%	1630 33%	7 37%	2470 49%	2 11%	459 9%	0 0%	27 1%	0 0%	478 10%
JAN-2021	12 80%	1701 34%	3 20%	2466 49%	0 0%	443 9%	0 0%	27 1%	0 0%	469 9%
FEB-2021	14 64%	1775 35%	5 23%	2482 49%	3 14%	420 8%	0 0%	24 0%	0 0%	458 9%
MAR-2021	23 72%	1843 35%	9 28%	2499 48%	0 0%	418 8%	0 0%	24 0%	0 0%	454 9%
APR-2021	15 75%	1904 36%	4 20%	2513 48%	1 5%	412 8%	0 0%	22 0%	0 0%	440 8%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2020	1617	21.98	1210	16.44	3562	48.41	87	1.18	56	0.76	826	11.23
FEB-2020	1573	21.46	1154	15.74	3644	49.71	85	1.16	58	0.79	816	11.13
MAR-2020	1540	20.85	1134	15.35	3755	50.83	85	1.15	50	0.68	823	11.14
APR-2020	1522	20.55	1129	15.24	3807	51.39	85	1.15	50	0.67	815	11.00
MAY-2020	1512	20.44	1111	15.02	3831	51.78	83	1.12	50	0.68	811	10.96
JUN-2020	1460	19.80	1085	14.71	3883	52.66	83	1.13	51	0.69	812	11.01
JUL-2020	1424	19.39	1059	14.42	3939	53.64	79	1.08	48	0.65	795	10.83
AUG-2020	1380	18.99	1028	14.14	3948	54.32	78	1.07	51	0.70	783	10.77
SEP-2020	1342	18.52	982	13.55	4003	55.23	76	1.05	52	0.72	793	10.94
OCT-2020	1310	18.00	965	13.26	4067	55.87	76	1.04	51	0.70	810	11.13
NOV-2020	1290	17.52	947	12.87	4143	56.28	75	1.02	49	0.67	857	11.64
DEC-2020	1275	17.31	926	12.57	4164	56.54	71	0.96	49	0.67	880	11.95
JAN-2021	1275	17.23	913	12.34	4201	56.79	68	0.92	46	0.62	895	12.10
FEB-2021	1233	16.69	894	12.10	4233	57.31	66	0.89	51	0.69	909	12.31
MAR-2021	1212	16.27	892	11.98	4284	57.52	64	0.86	51	0.68	945	12.69
APR-2021	1170	15.73	869	11.69	4331	58.24	62	0.83	44	0.59	960	12.91

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	4	7	400
JUN-2020	9	1	0	3	4	1	380
JUL-2020	12	3	0	0	2	4	500
AUG-2020	11	3	1	3	2	1	225
SEP-2020	9	3	2	1	0	0	71
OCT-2020	13	2	1	1	3	3	381
NOV-2020	12	0	1	0	2	6	710
DEC-2020	13	3	3	3	0	4	260
JAN-2021	10	1	4	0	1	2	170
FEB-2021	14	0	2	3	4	5	365
MAR-2021	24	4	5	3	5	5	280
APR-2021	9	2	1	1	1	4	370

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2020	12531	4027
FEB-2020	12561	4043
MAR-2020	12561	4033
APR-2020	12539	4009
MAY-2020	12529	3997
JUN-2020	12507	3975
JUL-2020	12484	3942
AUG-2020	12452	3918
SEP-2020	12415	3890
OCT-2020	12391	3876
NOV-2020	12405	3877
DEC-2020	12382	3838
JAN-2021	12390	3839
FEB-2021	12382	3833
MAR-2021	12381	3822
APR-2021	12370	3809

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
April 2021

N = 7436

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2021

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2021

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2021

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2021

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2021

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	5
	35-49	10	11	6
	50+	28	40	19
	Total HSDA:	44	57	30
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	73	98	53	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	397	536	302	
THOMPSON/CARIBOO/ SHUSWAP	20-34	19	19	11
	35-49	68	74	47
	50+	111	183	88
	Total HSDA:	198	276	146
Total HA:		712	967	531

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		712	967	531

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	573	777	431
Female	139	190	100

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	531	56	600	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	22	12
	5 years or more	11	8
	<5 years	11	10
	Total HSDA:	44	30
KOOTENAY BOUNDARY	10 years or more	48	32
	5 years or more	14	10
	<5 years	11	11
	Total HSDA:	73	53
OKANAGAN	10 years or more	245	181
	5 years or more	92	73
	<5 years	60	48
	Total HSDA:	397	302
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	114	84
	5 years or more	43	38
	<5 years	41	24
	Total HSDA:	198	146
Total HA:		712	531

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	429	309
	5 years or more	160	129
	<5 years	123	93
Total HA:		712	531

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	50	66	15	25
KOOTENAY BOUNDARY	76	126	26	47
OKANAGAN	226	962	55	288
THOMPSON/CARIBOO/SHUSWAP	141	530	37	128
Total:	493	1684	133	488

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	108

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	31	33	23
	35-49	96	103	65
	50+	243	331	187
	Total HSDA:	376	473	281
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1068	1448	799
FRASER SOUTH	0-19	5	5	5
	20-34	114	116	85
	35-49	318	354	260
	50+	579	865	477
	Total HSDA:	1016	1340	827
Total HA:		2460	3261	1907

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	12
	20-34	264	268	182
	35-49	758	826	583
	50+	1426	2155	1130
Total HA:		2460	3261	1907

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1857	2492	1460
Female	603	769	447

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1907	52	640	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	229	177
	5 years or more	84	59
	<5 years	63	45
	Total HSDA:	376	281
FRASER NORTH	10 years or more	634	454
	5 years or more	242	196
	<5 years	192	149
	Total HSDA:	1068	799
FRASER SOUTH	10 years or more	608	488
	5 years or more	212	168
	<5 years	196	171
	Total HSDA:	1016	827
Total HA:		2460	1907

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1471	1119
	5 years or more	538	423
	<5 years	451	365
Total HA:		2460	1907

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	140	508	28	56
FRASER NORTH	254	1591	47	213
FRASER SOUTH	220	1635	50	495
Total:	614	3734	125	764

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	188
FRASER NORTH	667
FRASER SOUTH	457
Total:	1312

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		343	498
RICHMOND	20-34	35	36	22
	35-49	45	47	36
	50+	115	163	90
	Total HSDA:	195	246	148
VANCOUVER	0-19	10	10	9
	20-34	445	460	285
	35-49	1323	1476	947
	50+	2911	5050	2123
	Total HSDA:	4689	6996	3364
Total HA:		5227	7740	3795

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	11	11	10
	20-34	503	519	323
	35-49	1449	1613	1047
	50+	3264	5597	2415
Total HA:		5227	7740	3795

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4614	6790	3352
Female	611	948	443

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3795	54	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	200	165
	5 years or more	79	64
	<5 years	64	54
	Total HSDA:	343	283
RICHMOND	10 years or more	115	85
	5 years or more	36	27
	<5 years	44	36
	Total HSDA:	195	148
VANCOUVER	10 years or more	2996	2072
	5 years or more	998	739
	<5 years	695	553
	Total HSDA:	4689	3364
Total HA:		5227	3795

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3311	2322
5 years or more	1113	830
<5 years	803	643
Total HA:	5227	3795

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	180	406	53	81
RICHMOND	43	293	8	91
VANCOUVER	638	11113	210	5306
Total:	861	11812	271	5478

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	6
RICHMOND	5
VANCOUVER	71
Total:	82

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		341	487
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		127	172
SOUTH VANCOUVER ISLAND	20-34	74	78	53
	35-49	188	216	149
	50+	494	788	377
	Total HSDA:	756	1082	579
Total HA:		1224	1741	954

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		1224	1741	954

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1011	1437	794
Female	213	304	160

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	954	55	570	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	203	897	78	199
NORTH VANCOUVER ISLAND	151	271	46	74
SOUTH VANCOUVER ISLAND	215	1849	41	557
Total:	569	3017	165	830

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	55
NORTH VANCOUVER ISLAND	40
SOUTH VANCOUVER ISLAND	118
Total:	213

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	199	161
	5 years or more	75	56
	<5 years	67	55
	Total HSDA:	341	272
NORTH VANCOUVER ISLAND	10 years or more	80	66
	5 years or more	31	21
	<5 years	16	16
	Total HSDA:	127	103
SOUTH VANCOUVER ISLAND	10 years or more	445	313
	5 years or more	157	137
	<5 years	154	129
	Total HSDA:	756	579
Total HA:		1224	954

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	724	540
5 years or more	263	214
<5 years	237	200
Total HA:	1224	954

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	*	*	0
	35-49	*	*	10
	50+	*	*	12
	Total HSDA:	41	52	22
NORTH WEST	20-34	*	6	0
	35-49	*	40	22
	50+	*	68	34
	Total HSDA:	70	114	56
NORTHERN INTERIOR	0-19	6	6	*
	20-34	22	24	*
	35-49	63	80	*
	50+	101	170	*
	Total HSDA:	192	280	143
Total HA:		303	446	221

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	29	33	*
	35-49	105	140	*
	50+	163	267	*
Total HA:		303	446	221

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	187	277	137
Female	116	169	84

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	221	51	540	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	25	*
	5 years or more	10	*
	<5 years	6	*
	Total HSDA:	41	22
NORTH WEST	10 years or more	41	32
	5 years or more	18	14
	<5 years	11	10
	Total HSDA:	70	56
NORTHERN INTERIOR	10 years or more	90	70
	5 years or more	63	44
	<5 years	39	29
	Total HSDA:	192	143
Total HA:		303	221

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	156	115
	5 years or more	91	64
	<5 years	56	42
Total HA:		303	221

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	40	62	3	*
NORTH WEST	81	166	17	*
NORTHERN INTERIOR	117	468	16	*
Total:	238	696	36	226

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	19
NORTHERN INTERIOR	13
Total:	39

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	5
	OKANAGAN	27	43	16
	THOMPSON/CARIBOO/SHUSWAP	25	49	19
	Total HA:	64	111	45
FRASER	FRASER EAST	36	48	26
	FRASER NORTH	54	91	43
	FRASER SOUTH	81	114	62
	Total HA:	171	253	131
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	27	50	22
	RICHMOND	8	13	5
	VANCOUVER	481	887	382
	Total HA:	516	950	409
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	83	42
	NORTH VANCOUVER ISLAND	18	27	14
	SOUTH VANCOUVER ISLAND	40	84	29
	Total HA:	109	194	85
NORTHERN	NORTH EAST	10	14	8
	NORTH WEST	29	62	24
	NORTHERN INTERIOR	73	113	63
	Total HA:	112	189	95
Total:		972	1697	765

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	613	1089	485
Female	359	608	280

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	765	52	510	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Monthly Report

Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Monthly Report

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Monthly Report

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

